The IV formulation has been administered rectally to children and adolescents using a short air-washed cannula. Rectal administration of flumazenil is not FDA-approved. Observe patient for at least 2 hours after administration for signs of resedation and hypoventilation. Care should be taken to avoid extravasation because the drug may be irritating to perivascular tissue. Inject over 15 to 30 seconds directly into the tubing of a free-flowing compatible IV infusion solution into a large vein to minimize injection site pain. Discard diluted injections after 24 hours. May be administered undiluted or diluted in a syringe with 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection. Patient must have a patent airway and established IV access prior to administration of flumazenil.

Flumazenil is administered intravenously however, ingestion of food during IV administration of flumazenil can increase the clearance of flumazenil by about 50%.

Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. Flumazenil does not reverse the actions of barbiturates, opiate agonists, or tricyclic antidepressants and is contraindicated in patients showing signs of cyclic antidepressant toxicity.įor storage information, see the specific product information within the How Supplied section. In pediatric patients, the intravenous formulation has also been administered intranasally and rectally these routes of administration are not FDA-approved. Flumazenil is administered by rapid IV injection because it is highly irritating, and care should be taken to avoid extravasation. Flumazenil will also antagonize the sedative actions of zolpidem and eszopiclone. Flumazenil is used to treat benzodiazepine overdose and to reverse benzodiazepine sedation during anesthesia. It is an imidazobenzodiazepine derivative. Flumazenil is a parenteral benzodiazepine antagonist.

Antidote for benzodiazepine poisoning